Shares of Eli Lilly & Co. LLY rallied 3.26% to $864.90 Monday, on what proved to be an all-around great trading session for ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target ...

This was the stock's second consecutive day of losses.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a market capitalization of $771.38 billion, a P/E ratio of 69.47, a PEG ratio of 1.40 and a beta of ...

Eli Lilly (LLY) has launched its weight-loss and diabetes drug, Mounjaro (tirzepatide), in India, securing a first-mover advantage in a market with a large obese population. This move positions ...

Eli Lilly stock has generated fantastic returns for investors over the past five years. The company possesses many lucrative growth opportunities to ensure it remains an excellent buy in the years ...

Feb. 26 (UPI) --Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.

Eli Lilly (LLY) announces it will invest $27 billion in four new manufacturing sites in the US. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to break down the news.